It is possible that the reduced expression of miR-564 leads to an enhanced expression of E2F3 which assists in the oncogenic activity of BCR-ABL and the growth advantage seen in CML-blast crisis cells. The gene discussed is E2F3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.